Published in Healthcare Mergers, Acquisitions and Ventures Week, May 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at ThromboGenics.
Report 1: ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS:BINV) announced today that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. The project is being developed within the framework of the alliance between ThromboGenics and BioInvent.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.